18/06/2019 12:00:00

Amarin to Present at the 2019 BMO Prescription For Success Healthcare Conference

BEDMINSTER, N.J. and DUBLIN, Ireland, June 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the 2019 BMO Prescription For Success Healthcare Conference on Tuesday, June 25, 2019, at 11:20 a.m. Eastern Time in New York City.

A live audio webcast of the presentation will be available at: https://www.amarincorp.com, and will be accessible at the same link for 30 days.

About Amarin

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in polyunsaturated fatty acids and lipid science. Vascepa® (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription in the United States, Lebanon and the United Arab Emirates.  Amarin’s commercial partners are pursuing additional regulatory approvals for Vascepa in Canada, China and the Middle East. For more information about Amarin, visit www.amarincorp.com.

Availability of other Information about Amarin

Investors and others should note that Amarin communicates with its investors and the public using the company website https://www.amarincorp.com/), the investor relations website (https://investor.amarincorp.com/), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts.  The information that Amarin posts on these channels and websites could be deemed to be material information.  As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis.  This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels.  The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information

Investor Relations:

Elisabeth Schwartz

Investor Relations

Amarin Corporation plc

In U.S.: +1 (908) 719-1315

investor.relations@amarincorp.com (investor inquiries)

Lee M. Stern

Trout Group 

In U.S.: +1 (646) 378-2992

lstern@troutgroup.com

Media Inquiries:

Gwen Fisher

Corporate Communications

Amarin Corporation plc

In U.S.: +1 (908) 325-0735

pr@amarincorp.com 

Amarin Corporation plc Logo

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
23 Aug
GEN
For Genmab investorer bliver september måned en hot affære - der kommer i hvert fald en stribe nyhed..
41
25 Aug
VELO
Det er interessant at kigge på Veloxis vækst og nuværende position i markedet for at regne frem til ..
38
21 Aug
I:NDX
Trump er en forretningsmand, der bevæger sig med en forretningsmands hastighed. Han er fløjtende lig..
21
22 Aug
 
Jeg synes hun gjorde det fremragende i sagen om Grønland og Trump.   Det vigtigste i en sådan situat..
20
20 Aug
VELO
Ny artikel på Medwatch:   15,5 pct. af amerikanske patienter, der får en nyretransplantation i dag, ..
20
20 Aug
PNDORA
  har du læst regnskabet - de forventer at tjene 4 mia i 2019 i forhold til en værdi af selskabet på..
18
24 Aug
GOMX
Har aktien:   GOMSPACE: TECKNAR AVTAL MED ESA VÄRT 1,4 MLN EUR 19:26STOCKHOLM (Nyhetsbyrån Direkt) R..
15
23 Aug
VELO
Netop i denne måned har jeg været på EuroInvestor i 1 år og manglede, for at sige det mildt, baggrun..
15
20 Aug
GEN
Lige i dette tilfælde er der måake ikke det vilde nye - men det er stadig data på disse konference d..
15
23 Aug
PNDORA
@Fqvist1 - ser er du er short fra 257, jf. din orientering d. 20.08. Jeg vil gerne gentage udbygge m..
14

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Maha Energy AB (publ) (“Maha” or the “Company”) Announces Filing of Second Quarter Report and Live Webcast
2
Texas Clinic of Chiropractic Declares Its Grand Opening in New Braunfels, Texas
3
FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Acer Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
4
PRF: Consolidated Unaudited Interim Report of AS PRFoods for the 4th quarter and 12 months of 2018/2019 financial year
5
WISeKey has submitted a confidential draft registration statement on Form 20-F under the US Securities Exchange Act of 1934 to the U.S. Securities and Exchange Commission (SEC)

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
26 August 2019 09:09:47
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB2 - 2019-08-26 10:09:47 - 2019-08-26 09:09:47 - 1000 - Website: OKAY